TITLE

ANTISENSE TO INITIATE "PROOF OF CONCEPT" STUDY OF ATL1101

PUB. DATE
January 2005
SOURCE
Worldwide Biotech;Jan2005, Vol. 17 Issue 1, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on a proof of concept study of ATL1101 in patients with psoriasis that will be conducted by Antisense Therapeutics Limited. Place wherein the study will take place; Information on ATL1101; Details of the proof of concept clinical trial; Background of Antisense Therapeutics.
ACCESSION #
15501429

 

Related Articles

  • Antisense Therapeutics releases preliminary ATL1102 phase I results targeting MS.  // PharmaWatch: CNS;March 2004, Vol. 3 Issue 3, p6 

    Presents the preliminary data from the phase I human clinical trial of ATL1102, an antisense drug targeting multiple sclerosis form Antisense Therapeutics Ltd. Dosage of the drug; Assessment on the safety and tolerability of increasing dose levels; Selection of appropriate dose levels and...

  • Antisense Licenses MS Drug to Teva.  // Bioworld Week;2/25/2008, Vol. 16 Issue 8, p3 

    The article reports on the certification of a multiple sclerosis drug by Antisense Therapeutics Ltd. to Teva Pharmaceuticals Ltd. in a deal that will directly net $2 million up front. It mentions that the agreement will offer an option for Teva to in-license ATL1102, a second generation...

  • Antisense signs licensing agreement with Teva.  // PharmaWatch: Biotechnology;Apr2008, Vol. 7 Issue 4, p13 

    The article reports on the license agreement signed by Antisense Therapeutics Ltd. (ANP) and Teva Pharmaceutical Industries Ltd. to create and commercialize ATL1102, an antisense inhibitor for patients with multiple sclerosis (MS). It was stated that ANP will conduct a Phase IIa clinical trial...

  • Janssen-Cilag: Stelara set to shine for psoriasis.  // PharmaWatch: Monthly Review;Mar2009, Vol. 8 Issue 3, p23 

    The article reports on the approval of Janssen-Cilag AG's Stelara for the treatment of plaque psoriasis in the Europe. A Phase III clinical trial has shown that 71% of patients treated with Selara has minimal signs of psoriasis by the end of the study. It is believed that Stelara, a human...

  • Antisense Licenses MS Drug to Teva for $2M Up Front.  // BioWorld Today;2/21/2008, Vol. 19 Issue 35, p2 

    The article reports on a licensing deal that was signed by Antisense Therapeutics Ltd. with Teva Pharmaceuticals for its second-generation antisense inhibitor of CD49d in multiple sclerosis. The deal is expected to net $2 million up front. In a related news, Antisense Therapeutics is in line to...

  • New data shows Amevive provides relief from psoriasis for a median of seven months.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p11 

    Focuses on the clinical research of Amevive, a drug for the treatment of psoriasis developed by Biogen Inc. Presentation of the clinical study of Amevive; Efficacy of the drug to treat psoriasis; Patients enrolled in the clinical research.

  • Genmab to drop development of psoriasis drug.  // PharmaWatch: Biotechnology;February 2004, Vol. 3 Issue 2, p7 

    Reports on the plan of Genmab AS to discontinue the development of HuMax-CD4, a drug candidate for treating psoriasis. Factors contributing to the company's decision; Failure of the study to present significant results for the drug combined; Indication of the drug's safety and efficacy during...

  • Products. Jaquiss, Ian; Sellers, L.J. // Pharmaceutical Executive;Sep99, Vol. 19 Issue 9, p176 

    Presents articles pertaining to pharmaceutical products in the United States. Completion of a statistical analysis of docosanol clinical data from Avanir Pharmaceutical requested by the Food and Drug Administration (FDA); New-drug application submitted by Connetics to FDA for Olux (clobetasol)...

  • Active Pharmaceutical Ingredient Watch.  // Chemical Market Reporter;11/18/2002, Vol. 262 Issue 18, p12 

    Presents news and developments relevant to the pharmaceutical industry compiled as of November 2002. Increase in drug production; Drug applications; Agreements; Clinical trials.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics